Literature DB >> 31070502

Spontaneous multiple cervical artery dissections after alemtuzumab.

Françoise Durand-Dubief1, Romain Marignier2, Yves Berthezene3, Judith Cottin4, Norbert Nighoghossian5, Sandra Vukusic6.   

Abstract

We report a case of multiple cervical artery dissections that occurred 4 days after a first course of alemtuzumab in a woman with relapsing-remitting multiple sclerosis and discuss its potential relationship and mechanisms of action. In particular, an arterial inflammatory process, secondary to cytokine release, could potentially lead to intimal thickening, luminal irregularities, stenosis, and ultimately occlusion. Occurrence of an unexpected serious adverse event, in our case, multiple cervical artery dissections, especially in a close time window after drug administration, questions a potential causal relationship with the drug or a simple coincidence.

Entities:  

Keywords:  Multiple sclerosis; alemtuzumab; cytokine release; multiple artery dissection; vessel wall inflammation

Year:  2019        PMID: 31070502     DOI: 10.1177/1352458519828663

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

Review 1.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.

Authors:  Gabrielle Macaron; Jenny Feng; Manikum Moodley; Mary Rensel
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.972

Review 2.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

Review 3.  Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

Authors:  Crystal Zheng; Indrani Kar; Claire Kaori Chen; Crystal Sau; Sophia Woodson; Alessandro Serra; Hesham Abboud
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.